Startup profile · funding coverage
OMass Therapeutics funding, valuation and investors
Oxford biotech developing small-molecule medicines in endocrinology and immunology.
Keep track of OMass Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$310M (£230M) · October 15, 2026
Latest known valuation
Undisclosed
Series C · October 15, 2026
Total disclosed equity funding
$310M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Oxford, United Kingdom
Investors in latest funding
Lead: Bain Capital Life Sciences , Forbion , Novo Holdings
Other: Janus Henderson Investors , SV Health Investors , Jefferson Life Sciences , Syncona , Oxford Science Enterprises , GV , Northpond Ventures , Sanofi Ventures , British Business Bank , University of Oxford
Overview
OMass Therapeutics uses native mass spectrometry and chemistry in its OdyssION discovery platform. Its investigational pipeline includes the MC2 receptor antagonist OMS1620 and an SLC15A4 inhibitor. It announced a $310M (£230M) Series C on October 15, 2026.
Why OMass Therapeutics is interesting
The financing can test whether discovery productivity translates into differentiated human clinical outcomes; round size is not evidence of efficacy or approval.
Product & use cases
Small-molecule discovery and development for endocrine and immune disorders.
Funding history (newest first)
Series C
2026-10-15 $310M (£230M) Valuation: Undisclosed- Bain Capital Life Sciences (lead)
- Forbion (lead)
- Novo Holdings (lead)
- Janus Henderson Investors (participant)
- SV Health Investors (participant)
- Jefferson Life Sciences (participant)
- Syncona (participant)
- Oxford Science Enterprises (participant)
- GV (participant)
- Northpond Ventures (participant)
- Sanofi Ventures (participant)
- British Business Bank (participant)
- University of Oxford (participant)
Investors in our directory
Funds linked from OMass Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Clinical differentiation, safety, dosing and development execution remain essential diligence tests. No comparative superiority is established here.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover OMass Therapeutics's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.